INVITRO DIFFERENTIATION OF T-CELLS CAPABLE OF MEDIATING THE REGRESSION OF ESTABLISHED SYNGENEIC TUMORS IN MICE
- 1 March 1987
- journal article
- research article
- Vol. 47 (5) , 1354-1360
Abstract
Previous studies have shown that successful adoptive immunotherapy of a newly induced, weakly immunogenic murine sarcoma, MCA 105, can be achieved either with fresh noncultured immune spleen cells or with immune cells after in vitro stimulation and expansion. In this study, we utilized in vivo and in vitro depletions with monoclonal antibodies (mAB) of T-cell subpopulations expressing the L3T4 or Lyt-2 antigen to investigate the phenotype of the T-cells that mediate in vivo tumor regression. The efficiency of depletion was assessed by flow microfluorometric analysis and by the ability of specifically treated spleen cell populations to generate allogenic cytotoxic T-lymphocytes. The therapeutic efficacy of adoptively transferred fresh noncultured MCA 105 immune cells was abrogated by in vivo administration of either L3T4 or Lyt-2 mAB to mice bearing 3-day established pulmonary metastases. In vitro treatment of fresh noncultured MCA 105 immune cells with their L3T4 or Lyt-2 mAB and complement also abrogated their antitumor efficacy confirming the initial findings. However, mixing L3T4 and Lyt-2 mAB and complement-treated MCA 105 immune cells reconstituted the antitumor efficacy indicating that cellular cooperation between these two lymphoid subpopulations was essential for the regression of established tumors. Unlike fresh noncultured immune cells, the antitumor efficacy of in vitro sensitized and expanded immune cells was abrogated by in vivo treatment with Lyt-2 but not with L3T4 mAb indicating Lyt-2+ cells alone played a major role in mediating the regression of tumors. These findings provide evidence for an in vitro-induced differentiation of therapeutic T-lymphocytes. Our results thus suggest that the antitumor activities expressed by the two type of cells may represent T-cells at different stage of immunological differentiation.This publication has 31 references indexed in Scilit:
- The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.The Journal of Immunology, 1980
- Blocking effect of lyt-2 antibodies on T cell functions.The Journal of Experimental Medicine, 1980
- Mouse alloantibodies capable of blocking cytotoxic T cell function. II. Further study on the relationship between the blocking antibodies and the products of the Lyt‐2 locusEuropean Journal of Immunology, 1980
- T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views.The Journal of Experimental Medicine, 1980
- In Vivo Elimination by Specific Effector Cells of an Established Syngeneic Rat Moloney Virus-Induced SarcomaThe Journal of Immunology, 1979
- Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antiseraProceedings of the National Academy of Sciences, 1979
- T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity.The Journal of Experimental Medicine, 1978
- INVITRO GROWTH OF MURINE T-CELLS .1. PRODUCTION OF FACTORS NECESSARY FOR T-CELL GROWTH1978
- Regression of Established Intradermal Tumors and Lymph Node Metastases in Guinea Pigs After Systemic Transfer of Immune Lymphoid CellsJNCI Journal of the National Cancer Institute, 1977
- Accurate Identification of Experimental Pulmonary Metastases2JNCI Journal of the National Cancer Institute, 1966